The use of monoclonal antibodies directed against SARS‐CoV‐2 in combination with molnupiravir in a patient with CVID and GLILD is safe.
All Keywords
【저자키워드】 COVID‐19, molnupiravir, Primary Immunodeficiency, CVID, Sotrovimab, GLILD,
【저자키워드】 COVID‐19, molnupiravir, Primary Immunodeficiency, CVID, Sotrovimab, GLILD,